Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
The Oncology Market: 2024 Year in Review
We look back at the oncology market and how it evolved in 2024, and add some thoughts about the year ahead.
The Joint Clinical Assessment: Expectations and Strategic Implications
The JCA represents a fundamental shift for European market entry, requiring biopharma companies to adopt new processes and resources to address its requirements.
Best Practice Commercialization Organization Study Report
We interviewed 24 CEOs, Chief Commercialization Officers, franchise leads, and other executives about how to build a "Best Practice" Commercialization Organization. Here's what they said...
7 "Make or Break" Factors for Emerging Biopharma Companies
Critical for any emerging company, whether its leaders intend to out-license lead assets, partner with other companies or, take assets to market.
Communicating the Value of Biopharma Assets to Potential Investors
Explore how a well-supported commercial proposition for an asset, even early in the development process, is critical to supporting a strong valuation.
Strategic Advisory
In a complex and rapidly evolving life science industry, we help clients with their most important strategic decisions. Blue Matter adds value at the product, portfolio, and corporate levels.
Cross-Functional Strategy
